Detail akcie Collegium Pharma online

Business Summary: Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Collegium Pharmaceutical Inc revenues increased 26% to $365.8M. Net income decreased 70% to $14.4M. Revenues reflect Nucynta IR segment increase from $71M to $154.2M, Xtampza segment increase of 9% to $104.3M. Net income was offset by General and administrative - Balancing increase of 88% to $127.7M (expense), Interest expense increase of 25% to $41.3M (expense).